Core Viewpoint - The company has achieved steady growth in performance, driven by global expansion and recovery in downstream industry demand, particularly in the injection molding machine sector [1][2][3]. Financial Performance - In H1 2024, the company reported revenue of 8.02 billion RMB, a year-on-year increase of 25.7%, and a net profit attributable to shareholders of 1.52 billion RMB, up 23.5%. Earnings per share stood at 0.95 RMB [1]. - The overall gross margin for H1 2024 was 32.3%, reflecting a 0.3 percentage point increase year-on-year, while the net profit margin was 19.0%, down 0.3 percentage points [1]. Injection Molding Machine Sales - The sales revenue from injection molding machines increased by 26.2% year-on-year to 7.70 billion RMB, with parts and service sales rising by 14.9% to 320 million RMB [2]. - The recovery in demand from downstream industries such as daily consumer goods, home appliances, and 3C products has significantly boosted sales, particularly for the Mars and Changfei series [2]. - The Jupiter series also saw stable growth due to investments in the overseas production capacity of the global automotive supply chain, especially in the new energy vehicle sector [2]. Global Market Expansion - Domestic revenue reached 5.18 billion RMB in H1 2024, a 33.7% increase, driven by the recovery in the daily consumer goods sector and the introduction of more energy-efficient and intelligent fifth-generation machines [3]. - Overseas revenue amounted to 2.84 billion RMB, up 13.2%, benefiting from structural adjustments in the global supply chain and the company's long-term investments in overseas markets [3]. - The company is committed to its "Five-Five" strategy, enhancing its global market presence across Asia, Europe, North America, and South America, with new factories under construction, including a manufacturing base in Serbia [3]. Future Outlook - The company has raised its net profit forecasts for 2024-2026 by 4.2%, 1.4%, and 0.1% to 3.00 billion, 3.25 billion, and 3.53 billion RMB, respectively, with corresponding EPS estimates of 1.88, 2.03, and 2.21 RMB [3]. - The ongoing equipment upgrades and increased overseas exports are expected to further enhance the company's performance [3].

Group 1: Company Overview and Market Trends - The company is actively responding to national policies promoting equipment upgrades, with specific subsidies for air compressor purchases in 2025, indicating a sustainable demand for compressors [2] - The company has increased R&D investments in oil-free screw compressors and screw vacuum pumps, maintaining steady sales growth in 2024, particularly in the semiconductor and new energy sectors [2] - The company is enhancing its product lines, including dry vacuum pumps for high-end industries, with expectations for increased sales volume and revenue share [2] Group 2: Domestic and International Market Expansion - The company is making significant progress in domestic substitution, achieving better market penetration in medical, electronics, and semiconductor industries, with recognition from major companies [2] - In 2024, overseas revenue grew by 18.22%, with a focus on Southeast Asian markets, and plans to expand sales channels through the Belt and Road Initiative [3] Group 3: Financial Performance and Profitability - The company maintains a stable gross margin due to a strong R&D team, increased competitiveness of high-end products, and a robust distributor network [3] - Cost control measures include improved internal management and strategic partnerships with suppliers, contributing to sustained operational performance [3] Group 4: Future Developments and Strategic Planning - The company is developing magnetic levitation centrifugal compressors, with a dedicated project team established to leverage existing technological foundations [3] - For 2025, the company anticipates continued growth, focusing on high-end model innovation, optimizing sales channels, and enhancing product competitiveness [3]

证券代码：836504 证券简称：博迅生物 公告编号：2025-046 上海博迅医疗生物仪器股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 投资者关系活动类别 √业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 二、 投资者关系活动情况 活动时间：2025 年 5 月 7 日（周三）15:00-16:00 活动地点：本次年度报告业绩说明会已在中证网"中证路演中心"举行 （https://www.cs.com.cn）。 □特定对象调研 回复：投资者您好！受客户采购习惯和春节假期因素影响，公司主营业务收 入存在一定的季节性波动，总体来看一季度收入占比相对较低，四季度收入占比 相对较高。 参会单位及人员：通过网络方式参与公司 2024 年年度报告业绩说明会的投 资者。 上市公司接待人员：公司董事长、总经理吕明杰先生；公司董事、营销中心 总监刘凇廷先生；公司财务负责人金曼女士；公司董事会秘书应芸女士；公司保 荐代表人刘洪泽先生。 三、 ...

Investment Rating - The report maintains an "Outperform" rating for the company [2] Core Insights - The company reported a revenue of 310 million yuan in 2024, a decrease of 9.1% year-on-year, and a net profit of 13 million yuan, down 71.0% year-on-year, which was below expectations [7] - In Q1 2025, the company achieved a revenue of 55 million yuan, an increase of 37.8% year-on-year, although it reported a net loss of 1 million yuan [7] - The company is expected to benefit from government policies aimed at promoting equipment updates and increasing technology spending, which could lead to a recovery in demand [7][10] Financial Data and Profit Forecast - The company’s total revenue is projected to be 342 million yuan in 2025, with a year-on-year growth rate of 10.2% [6] - The net profit forecast for 2025 is 43 million yuan, representing a significant increase of 230.5% compared to 2024 [6] - The company’s gross margin is expected to be 65.6% in 2025, slightly improving from 64.3% in Q1 2025 [6] Revenue Breakdown - In 2024, the company’s revenue from organic element analysis was 104 million yuan, down 23.0% year-on-year, while sample preparation revenue was 57 million yuan, down 18.7% [7] - The chromatography and spectroscopy segment generated 79 million yuan, with liquid chromatography instruments contributing 46 million yuan, an increase of 27.2% year-on-year [7] - The company’s international revenue reached 70 million yuan in 2024, up 12.2% year-on-year, driven by expanded overseas distribution channels [7] Strategic Initiatives - The company has been investing in automation and digitalization since 2014, enhancing its manufacturing capabilities [10] - The introduction of a digital core platform in 2024 is expected to support the production of customized non-standard components [10] - The report highlights the company’s proactive approach in recruiting high-quality talent during industry downturns to ensure long-term growth [7][10]

Investment Rating - The industry investment rating is "stronger than the market" indicating an expected performance that exceeds the market by more than 5% over the next six months [49]. Core Views - The chemical agents and blood products sectors are expected to perform outstandingly in 2024, with positive revenue and profit growth reported in the CXO and medical services (hospitals) sectors for Q1 2025 [4][5]. - The biopharmaceutical industry is anticipated to outperform the market overall [4]. Summary by Sections Industry Performance - As of April 30, 2025, 467 A-share biopharmaceutical companies reported their 2024 annual and Q1 2025 results. In 2024, 28 companies had revenue growth exceeding 30%, while 50 companies exceeded 20%, and 113 companies exceeded 10%. Approximately 220 companies reported positive revenue growth, while 246 experienced negative growth. On the profit side, 102 companies had profit growth over 30%, 132 over 20%, and 172 over 10%, with 218 maintaining positive profit growth and 249 facing negative growth [4]. - In Q1 2025, 24 companies reported revenue growth over 30%, 52 over 20%, and 109 over 10%, with 214 maintaining positive revenue growth and 251 reporting negative growth. For profits, 100 companies had growth over 30%, 120 over 20%, and 159 over 10%, with 220 maintaining positive profit growth and 240 facing negative growth [4]. Investment Strategies - Focus on "innovation," "going global," "equipment upgrades," and "consumption recovery." - **Innovation**: Invest in globally competitive innovative drugs and categories with significant market potential. Recommended companies include BeiGene, Dongcheng Pharmaceutical, and others [7]. - **Going Global**: Explore overseas markets for long-term opportunities, with companies like Mindray Medical and others highlighted [7]. - **Equipment Upgrades**: Expect support for medical equipment updates from central and local government financing, with companies like Mindray Medical and others recommended [7]. - **Consumption Recovery**: Anticipate recovery in quality sectors like ophthalmology and medical aesthetics, with companies such as Puri Eye Hospital and others suggested [7]. Key Companies to Watch - **Nocare Biopharma**: Expected to achieve over 1 billion yuan in revenue from its core product, with a 49% year-on-year sales increase. The company reported a gross margin of 86.3% and a significant reduction in losses [8]. - **Sihuan Pharmaceutical**: Strong fundamentals with core products maintaining growth, and a robust pipeline expected to yield multiple approvals from 2025 to 2027 [11]. - **China Biopharmaceutical**: Rapid revenue growth with an increasing share of innovative products, and a strong pipeline in oncology [13]. - **Aibo Medical**: Anticipated growth in high-end artificial lenses and recovery in consumption due to aging trends [23]. Industry News Highlights - BeiGene's Sonrotoclax NDA application has been accepted for review, indicating potential market entry for a new treatment for CLL/SLL [30]. - Novartis' Pluvicto has received acceptance for a new indication in China, expanding its market potential [31]. - The partnership between Fuhong Hanlin and Sandoz for HLX13 indicates a significant milestone in the commercialization of biosimilars [33].

Investment Rating - The industry investment rating is "stronger than the market" indicating an expected performance that exceeds the market by more than 5% over the next six months [50]. Core Insights - The chemical agents and blood products sectors showed outstanding performance in 2024, while the CXO and medical services (hospitals) sectors reported positive growth in both revenue and profit for Q1 2025 [4][5]. - As of April 30, 2025, among 467 selected A-share biopharmaceutical companies, 28 companies reported revenue growth exceeding 30% for 2024, while 50 companies had growth over 20% [4]. - In Q1 2025, 24 companies achieved revenue growth greater than 30%, and 100 companies reported profit growth exceeding 30% [4]. Summary by Sections Industry Performance - In 2024, the chemical agents and blood products sectors maintained positive growth in both revenue and profit [5]. - For Q1 2025, the CXO and medical services sectors also reported positive growth in revenue and profit [5]. Investment Strategy - Focus on "innovation," "going global," "equipment upgrades," and "consumption recovery" as key investment themes [7]. - Recommended companies for "innovation" include BeiGene, Dongcheng Pharmaceutical, and others [7]. - For "going global," companies like Mindray Medical and Sinopharm are highlighted [7]. - In "equipment upgrades," companies such as Mindray Medical and Aohua Medical are suggested [7]. - Under "consumption recovery," companies like Puri Eye Hospital and Tongce Medical are noted [7]. Key Companies to Watch - **Nocera Health**: Achieved revenue of 1.009 billion yuan in 2024, with a 49% year-on-year increase in sales of its core product, Obinutuzumab [8]. - **Sihuan Pharmaceutical**: Maintained a stable performance with core products continuing to grow [11]. - **China Biopharmaceutical**: Rapid revenue growth with an increasing proportion of innovative products expected to accelerate profit growth [13]. - **Aibao Medical**: The launch of its self-developed ICL lens is expected to drive significant revenue growth [23]. Industry News Highlights - BeiGene's Sonrotoclax new drug application has been accepted for review [30]. - Novartis' Lutetium-177 injection has been accepted for a new indication in China [31]. - Fuhong Hanlin signed a licensing agreement with Sandoz for HLX13 [33]. - BeiGene won a patent dispute, strengthening its market position for its BTK inhibitor [34].

Group 1 - The company held a performance briefing for the fiscal year 2024 and the first quarter of 2025 on May 7, 2025, via a video recording and online text interaction [2] - Key executives, including the General Manager and independent directors, participated in the briefing to address investor concerns within the scope of information disclosure [2] Group 2 - In 2024, the company achieved a revenue of RMB 1,647.57 million, representing a growth of 21.83% compared to the previous year, primarily driven by increased demand for passenger car crankshafts, especially hybrid crankshafts [3] - For 2025, the company plans to focus on "digital management, efficient operations, and high-quality development," while expanding its business in new energy electric drive gears and hybrid crankshafts [4] Group 3 - The automotive industry in China is expected to maintain a stable and positive growth trend in 2025, supported by proactive macro policies and the implementation of large-scale equipment updates and consumption upgrades [5] - The penetration rate of hybrid vehicles in the new energy passenger car market is anticipated to continue rising, creating strong incremental demand for domestic crankshaft manufacturers [5] Group 4 - The company currently does not have direct exports to the United States, with overseas revenue in 2024 amounting to approximately RMB 39.62 million, accounting for about 2.5% of its main business revenue, primarily targeting the Asian market [6] - In 2024, the company increased its investment in overseas non-U.S. markets, achieving significant results, including securing projects in France and Sweden [8] Group 5 - In 2024, the company made notable achievements in operational management, including a cost reduction of nearly RMB 23 million through supplier integration and material localization efforts [8] - The company successfully reduced finished goods inventory by 16% year-on-year, demonstrating effective inventory management [8]

问：国家倡设备更新，对公司有什么影响，是否可持续？ 证券之星消息，2025年5月7日东亚机械（301028）发布公告称公司于2025年5月7日接受机构调研，华福证 券俞能飞、农银汇理基金左腾飞、兴业基金董令飞参与。 具体内容如下： 2、公司拥有强大的经销商团队，大客户开发能力进一步提升，大客户数量稳定增加。 答：国家2024年不仅提倡大规模设备更新而且一直在加大设备更新支持力度，2025年初部分地区更是针对 空压机的采购，出台设备更新的具体补贴政策，2025年设备更新依旧可持续，这将带动压缩机需求的进一 步提升。公司也是紧抓设备更新的机遇，不断的研发投入，加大力度的对产品进行迭代升级，可以更好对 存量旧设备做替代。同时装备制造行业旧设备更新、产线升级等，公司产品压缩机、真空泵等也可以做为 配套设备进行销售。 问：无油螺杆空压机、螺杆真空泵和离心机的情况怎么样？ 答：2024年公司加大了研发投入，对无油螺杆空压机和螺杆真空泵等产品进行全面升级，提升了真空泵、 无油螺杆机的产品竞争力，该系列产品销售在2024年依旧保持稳健有升的态势，该系列产品已经销售给半 导体、新能源等行业公司。同时公司用于半导体、新能源等高端 ...

Group 1: Company Overview and Market Trends - The company is actively responding to national policies promoting equipment upgrades, which are expected to sustain demand for compressors in 2025 [2] - In 2024, the company increased R&D investment, enhancing the competitiveness of oil-free screw compressors and screw vacuum pumps, with sales showing a steady upward trend [2] - The company has successfully entered high-end markets such as semiconductors and new energy, with dry vacuum pumps achieving their first shipments [2] Group 2: Domestic Replacement and Export Business - The company has made significant progress in domestic replacement, with products being recognized in key industries like medical and electronics, further driving demand for compressors and vacuum pumps [2] - In 2024, overseas revenue grew by 18.22% year-on-year, with a focus on expanding markets in Southeast Asia [3] Group 3: Profitability and Future Outlook - The company maintains stable gross margins due to a strong R&D team, effective customer development, and cost control measures [3] - Management is optimistic about 2025, planning to continue innovation in high-end models and expand product lines while optimizing sales channels [3]

【广发环保 郭鹏】环保行业2024年报及2025年1季报总结：流水迢迢，硕果累累 建议关注：聚光科技、皖仪科技、瀚蓝环境、盈峰环境、军信股份、海螺创业、永兴股份、绿色动力、旺能环境 等 2024年板块硕果累累：现金流、分红、成长多重亮点 24年/25Q1板块实现扣非归母净利199/72亿元，同比-5.9%/+3.8%，其中亮点： 1）#公用事业化，24年固废+水务扣非归母净利182亿元（同比+11. 【广发环保 郭鹏】环保行业2024年报及2025年1季报总结：流水迢迢，硕果累累 建议关注：聚光科技、皖仪科技、瀚蓝环境、盈峰环境、军信股份、海螺创业、永兴股份、绿色动力、旺能环境 等 2024年板块硕果累累：现金流、分红、成长多重亮点 24年/25Q1板块实现扣非归母净利199/72亿元，同比-5.9%/+3.8%，其中亮点： 1）#公用事业化，24年固废+水务扣非归母净利182亿元（同比+11.2%）、占板块比重91%（同比+14pct）； 2）#自由现金流转正、分红提高，板块24年经营性/投资性现金流净额分别为547/-472亿元，#对应简略自由现金流 75.8亿元，#首次转正，板块典型41支高分红标的分红 ...